Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus

Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus

Objective: Plasmacytoid dendritic cells (pDCs) are a major source of Type-I Interferon (IFN-I), a key driver in cutaneous lupus erythematosus (CLE). Currently evaluated in Phase II clinical trial, 24F4A (BIIB059) is an antibody targeting BDCA2, an inhibitory receptor expressed on pDCs. Given that Hy...

Full description

Bibliographic Details
Main Authors: Agnes Gardet, Alex Pellerin, Christie-Ann McCarl, Rohan Diwanji, Wenting Wang, Douglas Donaldson, Nathalie Franchimont, Victoria P. Werth, Dania Rabah
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Immunology
Subjects:
cutaneous lupus erythematosus (CLE)
hydroxychloroquine
interferon
systemic lupus erythematosus (SLE)
BDCA2 blood dendritic cell antigen 2
toll like receptor (TLR)
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.00275/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.00275/full

Similar Items